GoAI
Get started
China Regenerative Medicine International Limited logo

China Regenerative Medicine International Limited

8158.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$0.235

+HK$0.014 · +6.33%

Aug 24, 3:41 PM HKT

8158.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.

Industry
Biotechnology
Sector
Healthcare
Headquarters
HK
CEO
Chuang Wang
Listed since
Jul 18, 2001
Employees
30

Market position

Volume
0
0× average
Average volume
41.6K
Average daily volume
Market cap
71.5M HKD
Beta
-0.67
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
170.92M HKD
P/E (TTM)
2.59×
P/B (TTM)
1.34×
P/S (TTM)
0.99×
EV / EBITDA
20.68×
Earnings yield
21.54%
Free cash flow yield
3.15%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
58.17%
Operating margin
-2.21%
Net margin
38.20%
Return on equity
51.47%
Return on assets
16.38%
Return on invested capital
-0.29%

Financial health

Debt / equity
0.96×
Current ratio
1.14×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends115%16%-83%-182%Gross margin, FY2021: 23.94%Gross margin, FY2022: 90.58%Gross margin, FY2023: 27.95%Gross margin, FY2024: 63.62%Gross margin, FY2025: 58.17%Operating margin, FY2021: 20.84%Operating margin, FY2022: 29.59%Operating margin, FY2023: -157.03%Operating margin, FY2024: 20.33%Operating margin, FY2025: -2.21%Net margin, FY2021: 18.32%Net margin, FY2022: 10.97%Net margin, FY2023: -154.99%Net margin, FY2024: 19.59%Net margin, FY2025: 38.20%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 23.94%. Gross margin FY2022 90.58%. Gross margin FY2023 27.95%. Gross margin FY2024 63.62%. Gross margin FY2025 58.17%. Operating margin FY2021 20.84%. Operating margin FY2022 29.59%. Operating margin FY2023 -157.03%. Operating margin FY2024 20.33%. Operating margin FY2025 -2.21%. Net margin FY2021 18.32%. Net margin FY2022 10.97%. Net margin FY2023 -154.99%. Net margin FY2024 19.59%. Net margin FY2025 38.20%.

Income trends

Revenue

72.06M HKD-20.48%

Operating income

−1.59M HKD−20.02M HKD

Net income

27.53M HKD+55.05%
Income trends across reported periods322.1M HKD165.29M HKD8.49M HKD−148.31M HKDRevenue, FY2021: 282.9M HKDRevenue, FY2022: 41.54M HKDRevenue, FY2023: 69.49M HKDRevenue, FY2024: 90.62M HKDRevenue, FY2025: 72.06M HKDOperating income, FY2021: 58.96M HKDOperating income, FY2022: 12.29M HKDOperating income, FY2023: −109.11M HKDOperating income, FY2024: 18.43M HKDOperating income, FY2025: −1.59M HKDNet income, FY2021: 51.83M HKDNet income, FY2022: 4.56M HKDNet income, FY2023: −107.7M HKDNet income, FY2024: 17.75M HKDNet income, FY2025: 27.53M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 282.9M HKD. Revenue FY2022 41.54M HKD. Revenue FY2023 69.49M HKD. Revenue FY2024 90.62M HKD. Revenue FY2025 72.06M HKD. Operating income FY2021 58.96M HKD. Operating income FY2022 12.29M HKD. Operating income FY2023 −109.11M HKD. Operating income FY2024 18.43M HKD. Operating income FY2025 −1.59M HKD. Net income FY2021 51.83M HKD. Net income FY2022 4.56M HKD. Net income FY2023 −107.7M HKD. Net income FY2024 17.75M HKD. Net income FY2025 27.53M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue72.06M HKD90.62M HKD69.49M HKD41.54M HKD282.9M HKD
Cost of goods sold30.14M HKD32.96M HKD50.06M HKD3.91M HKD215.17M HKD
Gross profit41.92M HKD57.65M HKD19.42M HKD37.62M HKD67.73M HKD
Selling, general, and administrative42.36M HKD51.52M HKD45.54M HKD25.82M HKD47.45M HKD
Operating expenses43.51M HKD38.77M HKD128.54M HKD25.82M HKD8.77M HKD
Interest income17.96M HKD17.58M HKD12K HKD1K HKD11K HKD
Interest expense1.2M HKD1.13M HKD979K HKD781K HKD736K HKD
Depreciation and amortization9.86M HKD10.96M HKD11.32M HKD5.39M HKD78K HKD
Operating income−1.59M HKD18.43M HKD−109.11M HKD12.29M HKD58.96M HKD
Net income27.53M HKD17.75M HKD−107.7M HKD4.56M HKD51.83M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.080.03-0.01-0.06Q2 '23Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q4 '24Q1 '25
Q2 2023, reported Apr 11, 2023: actual -0.021, estimate —, surprise —, Comparison unavailable. Q2 2023, reported May 16, 2023: actual 0.001, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 15, 2023: actual 0.039, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 15, 2023: actual -0.021, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Apr 30, 2024: actual 0.028, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 24, 2024: actual 0.028, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 16, 2024: actual 0.002, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 0.002, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates72.99M52.05M31.11M10.17MQ2 '23Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q4 '24Q1 '25
Q2 2023, reported Apr 11, 2023: actual 68.47M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported May 16, 2023: actual 54.05M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 15, 2023: actual 46.04M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 15, 2023: actual 11.97M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Apr 30, 2024: actual 29.89M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 24, 2024: actual 29.89M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 16, 2024: actual 15.42M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 15.42M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Sep 6, 2023

1:10

Stock split

Effective May 16, 2019

1:20

Stock split

Effective Aug 29, 2007

4:1

8158.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 8158.HK

research.disclaimer